Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox.

Mehta RS.

J Clin Oncol. 2008 Jul 1;26(19):3286-8; author reply 3288. doi: 10.1200/JCO.2008.17.1116. No abstract available.

PMID:
18591566
2.

Triple-negative breast cancer: a short review.

Elias AD.

Am J Clin Oncol. 2010 Dec;33(6):637-45. doi: 10.1097/COC.0b013e3181b8afcf. Review.

PMID:
20023571
3.

Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy.

Montemurro F, Aglietta M.

Endocr Relat Cancer. 2009 Dec;16(4):1091-102. doi: 10.1677/ERC-09-0033. Epub 2009 Sep 2. Review.

4.

Adjuvant chemotherapy for early-stage breast cancer.

McArthur HL, Hudis CA.

Hematol Oncol Clin North Am. 2007 Apr;21(2):207-22. Review.

PMID:
17512445
5.

[Neoadjuvant systemic chemotherapy for patients with operable breast cancer].

Zhang B, Zhang Q.

Zhonghua Zhong Liu Za Zhi. 2007 Mar;29(3):161-5. Review. Chinese. No abstract available.

PMID:
17649628
6.

Disease related indicators for a proper choice of adjuvant treatments.

Hayes DF.

Breast. 2011 Oct;20 Suppl 3:S162-4. doi: 10.1016/S0960-9776(11)70317-4. Review.

PMID:
22015287
7.

Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.

Venkitaraman R.

Expert Rev Anticancer Ther. 2010 Feb;10(2):199-207. doi: 10.1586/era.09.189. Review.

PMID:
20131996
8.

Quality indicators for the care of breast cancer in vulnerable elders.

Naeim A, Sawhney R, MacLean CH, Sanati H.

J Am Geriatr Soc. 2007 Oct;55 Suppl 2:S258-69. Review. No abstract available.

PMID:
17910546
9.

Therapeutic strategies for triple-negative breast cancer.

Tan AR, Swain SM.

Cancer J. 2008 Nov-Dec;14(6):343-51. doi: 10.1097/PPO.0b013e31818d839b. Review.

PMID:
19060597
10.

Extended adjuvant chemotherapy in endocrine non-responsive disease.

Colleoni M, Munzone E.

Breast. 2013 Aug;22 Suppl 2:S161-4. doi: 10.1016/j.breast.2013.07.031. Review.

PMID:
24074780
11.

Pharmacotherapy of triple-negative breast cancer.

Arslan C, Dizdar O, Altundag K.

Expert Opin Pharmacother. 2009 Sep;10(13):2081-93. doi: 10.1517/14656560903117309. Review.

PMID:
19640211
12.

What is triple-negative breast cancer?

Irvin WJ Jr, Carey LA.

Eur J Cancer. 2008 Dec;44(18):2799-805. doi: 10.1016/j.ejca.2008.09.034. Epub 2008 Nov 12. Review.

PMID:
19008097
13.

[Hormone treatment of breast cancer].

Gröhn P.

Duodecim. 1991;107(8):603-10. Review. Finnish. No abstract available.

PMID:
1364913
14.

[Molecular subtypes and individualized treatment of breast cancer].

Xu BH, Zhang P.

Zhonghua Zhong Liu Za Zhi. 2010 Sep;32(9):641-4. Review. Chinese. No abstract available.

PMID:
21122374
15.

Triple-negative breast cancers: a view from 10,000 feet.

Ray M, Polite BN.

Cancer J. 2010 Jan-Feb;16(1):17-22. doi: 10.1097/PPO.0b013e3181d3eef5. Review.

PMID:
20164686
16.

Triple-negative breast cancer: role of the androgen receptor.

Gucalp A, Traina TA.

Cancer J. 2010 Jan-Feb;16(1):62-5. doi: 10.1097/PPO.0b013e3181ce4ae1. Review. Erratum in: Cancer J. 2010 Nov-Dec;16(6):643.

PMID:
20164692
17.

[Early-stage breast cancer - strategies for adjuvant systemic therapy].

Görner M, Just M, Gerull S.

Handchir Mikrochir Plast Chir. 2008 Aug;40(4):230-8. doi: 10.1055/s-2008-1038926. Epub 2008 Aug 20. Review. German.

PMID:
18716990
18.

[Detection and treatment of ductal carcinoma of the breast].

Semiglazov VV, Tabagua TT, Matsko DE.

Vopr Onkol. 2011;57(6):699-701. Review. Russian. No abstract available.

PMID:
22416383
19.

Endocrine therapy of breast cancer.

Goldhirsch A, Colleoni M, Gelber RD.

Ann Oncol. 2002;13 Suppl 4:61-8. Review. No abstract available.

PMID:
12401668
20.

Triple-negative breast cancer in the older population.

Aapro M, Wildiers H.

Ann Oncol. 2012 Aug;23 Suppl 6:vi52-5. Review.

PMID:
23012304

Supplemental Content

Support Center